Abstract |
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose-escalation part in 12 patients, we showed that BV-DHAP is feasible. This Phase II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP ( dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1 and cytarabine 2x2g/m2; day 2). Patients with a metabolic partial response (mPR) or mCR proceeded to HDC/auto-PBSCT. Based on independent central FDG-PET-CT review, 42 of 52 evaluable patients (81% [95% CI: 67-90]) achieved an mCR before HDC/auto-PBSCT, five had an mPR and five had progressive disease (three were not evaluable). After HDC/auto-PBSCT, four patients with an mPR converted to an mCR. The 2-year PFS was 74% [95% CI: 63-86], and the overall survival 95% [95% CI: 90-100]. Toxicity was manageable and mainly consisted of grade 3/4 hematological toxicity, fever, nephrotoxicity, ototoxicity (grade 1/2) and transiently elevated liver enzymes during BV-DHAP. Eighteen patients developed new onset peripheral neuropathy (maximum grade 1/2) and all recovered. In conclusion, BV-DHAP is a very effective salvage regimen in R/R cHL patients, but patients should be monitored closely for toxicity. ClinicalTrials.gov identifier: NCT02280993.
|
Authors | Marie José Kersten, Julia Driessen, Josée M Zijlstra, Wouter J Plattel, Franck Morschhauser, Pieternella J Lugtenburg, Pauline Brice, Martin Hutchings, Thomas Gastinne, Roberto Liu, Coreline N Burggraaff, Marcel Nijland, Sanne H Tonino, Anne I J Arens, Roelf Valkema, Harm van Tinteren, Marta Lopez-Yurda, Arjan Diepstra, Daphne De Jong, Anton Hagenbeek |
Journal | Haematologica
(Haematologica)
Vol. 106
Issue 4
Pg. 1129-1137
(04 01 2021)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 32273476
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cytarabine
- Dexamethasone
- Brentuximab Vedotin
- Cisplatin
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Brentuximab Vedotin
- Cisplatin
- Cytarabine
(therapeutic use)
- Dexamethasone
(therapeutic use)
- Hodgkin Disease
(drug therapy)
- Humans
- Neoplasm Recurrence, Local
- Positron Emission Tomography Computed Tomography
- Recurrence
- Salvage Therapy
- Treatment Outcome
|